FGF23 and chronic kidney disease: From a diagnostic perspective, FGF-23 holds promise as a biomarker for early CKD-related cardiovascular risk, but its implementation in clinical practice is limited by assay variability (e.g., intact vs. C-terminal FGF-23 assays), lack of standardized cutoffs, and the complexity of its dual endocrine and paracrine actions.